Home > Gastroenterology > UEGW 2021 > Updates in Biologics > Long-term efficacy data of dupilumab for eosinophilic oesophagitis

Long-term efficacy data of dupilumab for eosinophilic oesophagitis

Presented By
Dr Evan Dellon, University of North Carolina, NC, USA
Conference
UEGW 2021
Trial
Phase 3, LIBERTY EoE TREET
Dupilumab showed maintained patient benefits in an eosinophilic oesophagitis (EoE) population. The 28-week extended treatment period of the randomised, double-blind, placebo-controlled, phase 3 LIBERTY EoE TREET trial showed sustained symptomatic, histologic, and endoscopic benefits of dupilumab. The drug was well tolerated and few severe adverse events were reported. Dupilumab is a human monoclonal antibody inhibiting IL-4 and IL-13 signalling. Part A of the LIBERTY EoE TREET trial (NCT03633617) demonstrated that 300 mg dupilumab (subcutaneous injection, once weekly) was more efficacious than placebo after 24 weeks in a symptomatic, severely inflamed population of EoE patients. Part C of the trial investigated the long-term efficacy and safety of dupilumab in a 28-week extended treatment period [1]. All patients (n=77) who completed part A were enrolled in part C ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on